These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23812262)

  • 21. Can 'double blockbuster' strengthen Amgen's backbone?
    Sheridan C
    Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
    [No Abstract]   [Full Text] [Related]  

  • 22. Reinventing clinical trials.
    Allison M
    Nat Biotechnol; 2012 Jan; 30(1):41-9. PubMed ID: 22231093
    [No Abstract]   [Full Text] [Related]  

  • 23. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 24. Market watch: Upcoming market catalysts in Q3 2017.
    Nghiem S
    Nat Rev Drug Discov; 2017 Jul; 16(7):449. PubMed ID: 28620177
    [No Abstract]   [Full Text] [Related]  

  • 25. Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs.
    Nat Rev Drug Discov; 2011 Dec; 10(12):890. PubMed ID: 22129980
    [No Abstract]   [Full Text] [Related]  

  • 26. The bitterest pill.
    Nature; 2006 Nov; 444(7119):532-3. PubMed ID: 17136064
    [No Abstract]   [Full Text] [Related]  

  • 27. Market watch: key clinical and regulatory events in Q2 2010.
    Hay M
    Nat Rev Drug Discov; 2010 Apr; 9(4):261. PubMed ID: 20357797
    [No Abstract]   [Full Text] [Related]  

  • 28. Future therapeutic options for celiac disease.
    Sollid LM; Khosla C
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):140-7. PubMed ID: 16265155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 30. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can personalized drugs pay off?
    Stipp D
    Fortune; 2002 May; 145(10):168. PubMed ID: 12025349
    [No Abstract]   [Full Text] [Related]  

  • 33. Sense and antisense for investors.
    Jacobs T
    Nat Biotechnol; 2002 Jun; 20(6):543. PubMed ID: 12042846
    [No Abstract]   [Full Text] [Related]  

  • 34. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.
    Enna SJ; Williams M
    Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649
    [No Abstract]   [Full Text] [Related]  

  • 35. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharma consolidates its grip on post-antibody landscape.
    Sheridan C
    Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
    [No Abstract]   [Full Text] [Related]  

  • 37. Trial watch: Phase II failures: 2008-2010.
    Arrowsmith J
    Nat Rev Drug Discov; 2011 May; 10(5):328-9. PubMed ID: 21532551
    [No Abstract]   [Full Text] [Related]  

  • 38. Quantifying the magnitude and cost of collecting extraneous protocol data.
    Getz KA; Stergiopoulos S; Marlborough M; Whitehill J; Curran M; Kaitin KI
    Am J Ther; 2015; 22(2):117-24. PubMed ID: 23429165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can Merck stand alone?
    Warner M
    Fortune; 2001 Jul; 144(2):62. PubMed ID: 11471356
    [No Abstract]   [Full Text] [Related]  

  • 40. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.